Metastatic bone cancer is an incurable disease and one of the most complex cancers to treat. Due to the high dose, tumour imaging is currently performed at the beginning and end of standard particle radio-therapy (PRT), making personalised treatment difficult. The main goal of BoneOscopy is to develop a radically new technology to enable informed medical decisions by monitoring bone cancer on a daily basis during PRT. At the heart of BoneOscopy is the ability to detect prompt gamma (PGs) emitted by cancer during PRT and separate them from healthy tissue, unlocking the full potential of spectroscopic analysis without the need for additional dose. The development of a highly specialised detection and collimation system will enable accurate spectroscopic analysis of a very small volume or region within the cancer. As the number of PRT centres grows, we anticipate that within 10 years BoneOscopy will benefit all patients treated with proton and carbon ions. The objectives of BoneOscopy will be achieved by its interdisciplinary consortium, which brings together six partners from five European countries with key expertise in bioengineering and PRT (DKFZ), medical physics and engineering (CSIC), fast electronics for PRT (LIP), Monte Carlo simulations and clinical PRT experience (THM), turnkey software for high performance medical devices (Cosylab) and EU project management, communication and dissemination (accelCH). If achieved, the proposed science-to-technology breakthrough will have a transformative impact on current cancer treatment by providing a safe, personalised and quantitative measure of daily treatment efficacy, thereby contributing to the global fight against cancer. In summary, BoneOscopy will lead to a significant reduction in the health burden in Europe and worldwide, improved quality of life for patients, reduced costs for healthcare systems and improved sustainability of healthcare.

Particle physics is at the forefront of the ERA, attracting a global community of more than 10,000 scientists. With the upgrade of the LHC and the preparation of new experiments, the community will have to overcome unprecedented challenges in order to answer fundamental questions concerning the Higgs boson, neutrinos, and physics beyond the Standard Model. Major developments in detector technology are required to ensure the success of these endeavours. The AIDA-2020 project brings together the leading European infrastructures in detector development and a number of academic institutes, thus assembling the necessary expertise for the ambitious programme of work. In total, 19 countries and CERN are involved in this programme, which follows closely the priorities of the European Strategy for Particle Physics. AIDA-2020 aims to advance detector technologies beyond current limits by offering well-equipped test beam and irradiation facilities for testing detector systems under its Transnational Access programme. Common software tools, micro-electronics and data acquisition systems are also provided. This shared high-quality infrastructure will ensure optimal use and coherent development, thus increasing knowledge exchange between European groups and maximising scientific progress. The project also exploits the innovation potential of detector research by engaging with European industry for large-scale production of detector systems and by developing applications outside of particle physics, e.g. for medical imaging. AIDA-2020 will lead to enhanced coordination within the European detector community, leveraging EU and national resources. The project will explore novel detector technologies and will provide the ERA with world-class infrastructure for detector development, benefiting thousands of researchers participating in future particle physics projects, and contributing to maintaining Europe's leadership of the field.